Madrigal Pharmaceuticals Inc
NASDAQ:MDGL

Watchlist Manager
Madrigal Pharmaceuticals Inc Logo
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Watchlist
Price: 566.93 USD 1.6% Market Closed
Market Cap: 12.9B USD

Madrigal Pharmaceuticals Inc
Total Equity

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Madrigal Pharmaceuticals Inc
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Total Equity
$625.7m
CAGR 3-Years
288%
CAGR 5-Years
17%
CAGR 10-Years
26%
Abbvie Inc
NYSE:ABBV
Total Equity
-$2.6B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Total Equity
$21.5B
CAGR 3-Years
1%
CAGR 5-Years
4%
CAGR 10-Years
2%
Amgen Inc
NASDAQ:AMGN
Total Equity
$9.6B
CAGR 3-Years
38%
CAGR 5-Years
-3%
CAGR 10-Years
-10%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Equity
$17.3B
CAGR 3-Years
10%
CAGR 5-Years
16%
CAGR 10-Years
34%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Equity
$31B
CAGR 3-Years
13%
CAGR 5-Years
25%
CAGR 10-Years
25%
No Stocks Found

Madrigal Pharmaceuticals Inc
Glance View

In the competitive and complex landscape of pharmaceuticals, Madrigal Pharmaceuticals Inc. has carved a niche for itself by focusing on the development of innovative therapies for metabolic and liver diseases. Founded with the visionary zeal to address unmet medical needs, Madrigal's journey is grounded in its dedication to advancing science and transforming patient care. The company's primary research and development efforts center around addressing non-alcoholic steatohepatitis (NASH), a significant liver condition that lacks approved treatments. With a keen eye on scientific innovation, Madrigal invests heavily in creating solutions for conditions that are not only challenging but also growing in prevalence, thus embodying the dual mission of driving better health outcomes and capturing market opportunities. Madrigal's business model is largely reliant on the successful progression of its lead candidate, resmetirom, through clinical trials and regulatory approval processes. This strategy, typical in the pharmaceutical arena, involves rigorous stages of testing to ensure efficacy and safety, aiming to bring the drug to market where it can address the substantial need. Revenue generation for Madrigal is intrinsically linked to licensing agreements, strategic partnerships, and eventual drug sales post-approval. This approach necessitates significant initial investment and patience, with the expectation of substantial returns contingent upon successful product commercialization. Through this focus, Madrigal advances towards not only improving the therapeutic landscape for liver diseases but also carving out a significant presence in the biotech market.

MDGL Intrinsic Value
HIDDEN
Show

See Also

What is Madrigal Pharmaceuticals Inc's Total Equity?
Total Equity
625.7m USD

Based on the financial report for Sep 30, 2025, Madrigal Pharmaceuticals Inc's Total Equity amounts to 625.7m USD.

What is Madrigal Pharmaceuticals Inc's Total Equity growth rate?
Total Equity CAGR 10Y
26%

Over the last year, the Total Equity growth was -19%. The average annual Total Equity growth rates for Madrigal Pharmaceuticals Inc have been 288% over the past three years , 17% over the past five years , and 26% over the past ten years .

Back to Top